Document Detail


Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.
MedLine Citation:
PMID:  21860025     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma; however, gene expression profiling (GEP) based signatures may enable more specific risk categorization. We examined the utility of 2 GEP-based risk stratification systems among patients undergoing initial therapy with lenalidomide in the context of a phase 3 trial. Among 45 patients studied at baseline, 7 (16%) and 10 (22%), respectively, were high-risk using the GEP70 and GEP15 signatures. The median overall survival for the GEP70 high-risk group was 19 months versus not reached for the rest (hazard ratio = 14.1). Although the medians were not reached, the GEP15 also predicted a poor outcome among the high-risk patients. The C-statistic for the GEP70, GEP15, and FISH based risk stratification systems was 0.74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475.
Authors:
Shaji K Kumar; Hajime Uno; Susanna J Jacobus; Scott A Van Wier; Greg J Ahmann; Kimberly J Henderson; Natalie S Callander; Jessica L Haug; David S Siegel; Philip R Greipp; Rafael Fonseca; S Vincent Rajkumar
Related Documents :
21934565 - Infections missed by urethral-only screening for chlamydia or gonorrhea detection among...
6996405 - The place of oestriol therapy after menopause.
18235425 - Testosterone increases amygdala reactivity in middle-aged women to a young adulthood le...
21757655 - Circulating interleukin-10 and risk of cardiovascular events: a prospective study in th...
21860025 - Impact of gene expression profiling-based risk stratification in patients with myeloma ...
25460285 - Hif1a and mif as potential predictive mrna biomarkers of pre-eclampsia: a longitudinal ...
Publication Detail:
Type:  Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Extramural     Date:  2011-08-22
Journal Detail:
Title:  Blood     Volume:  118     ISSN:  1528-0020     ISO Abbreviation:  Blood     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-24     Completed Date:  2011-12-20     Revised Date:  2014-09-12    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4359-62     Citation Subset:  AIM; IM    
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00098475
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antineoplastic Agents / therapeutic use*
Chromosome Aberrations
Dexamethasone / therapeutic use*
Female
Gene Expression Profiling*
Humans
Male
Middle Aged
Multiple Myeloma / drug therapy*,  genetics*
Survival Analysis
Thalidomide / analogs & derivatives*,  therapeutic use
Treatment Outcome
Grant Support
ID/Acronym/Agency:
CA13650/CA/NCI NIH HHS; CA21115/CA/NCI NIH HHS; CA23318/CA/NCI NIH HHS; CA66636/CA/NCI NIH HHS; CA90628/CA/NCI NIH HHS; CA93842/CA/NCI NIH HHS; R01 CA083724/CA/NCI NIH HHS; U24 CA114737/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 191732-72-6/lenalidomide; 4Z8R6ORS6L/Thalidomide; 7S5I7G3JQL/Dexamethasone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gene induction and repression during terminal erythropoiesis are mediated by distinct epigenetic cha...
Next Document:  Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.